Literature DB >> 31604914

ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer.

Arun Kanakkanthara1,2, Catherine J Huntoon1, Xiaonan Hou3, Minzhi Zhang3, Ethan P Heinzen4, Daniel R O'Brien4, Ann L Oberg4, S John Weroha3, Scott H Kaufmann1,2, Larry M Karnitz5,6.   

Abstract

Reduced BRCA1 expression causes homologous recombination (HR) repair defects in high-grade serous ovarian cancers (HGSOCs). Here, we demonstrate that BRCA1 is transcriptionally activated by a previously unknown function of ZC3H18. We show that ZC3H18 is a DNA-binding protein that interacts with an E2F site in the BRCA1 promoter where it facilitates recruitment of E2F4 to an adjacent E2F site to promote BRCA1 transcription. Consistent with ZC3H18 role in activating BRCA1 expression, ZC3H18 depletion induces BRCA1 promoter methylation, reduces BRCA1 expression, disrupts HR, and sensitizes cells to DNA crosslinkers and poly(ADP-ribose) polymerase inhibitors. Moreover, in patient-derived xenografts and primary HGSOC tumors, ZC3H18 and E2F4 mRNA levels are positively correlated with BRCA1 mRNA levels, further supporting ZC3H18 role in regulating BRCA1. Given that ZC3H18 lies within 16q24.2, a region with frequent copy number loss in HGSOC, these findings suggest that ZC3H18 copy number losses could contribute to HR defects in HGSOC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31604914      PMCID: PMC6789141          DOI: 10.1038/s41467-019-12610-x

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  58 in total

1.  ChIP and Re-ChIP assays: investigating interactions between regulatory proteins, histone modifications, and the DNA sequences to which they bind.

Authors:  Agnieszka D Truax; Susanna F Greer
Journal:  Methods Mol Biol       Date:  2012

2.  Homologous recombination assay for interstrand cross-link repair.

Authors:  Koji Nakanishi; Francesca Cavallo; Erika Brunet; Maria Jasin
Journal:  Methods Mol Biol       Date:  2011

3.  BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Authors:  Britta Stordal; Kirsten Timms; Angela Farrelly; Danielle Gallagher; Steven Busschots; Mickaël Renaud; Julien Thery; Deborah Williams; Jennifer Potter; Thanh Tran; Greg Korpanty; Mattia Cremona; Mark Carey; Jie Li; Yang Li; Ozlem Aslan; John J O'Leary; Gordon B Mills; Bryan T Hennessy
Journal:  Mol Oncol       Date:  2013-01-31       Impact factor: 6.603

4.  Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.

Authors:  Ranjit S Bindra; Shannon L Gibson; Alice Meng; Ulrica Westermark; Maria Jasin; Andrew J Pierce; Robert G Bristow; Marie K Classon; Peter M Glazer
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

5.  BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.

Authors:  T Ignatov; H Eggemann; S D Costa; A Roessner; T Kalinski; A Ignatov
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-14       Impact factor: 4.553

Review 6.  Targeting DNA repair: the genome as a potential biomarker.

Authors:  Ksenija Nesic; Matthew Wakefield; Olga Kondrashova; Clare L Scott; Iain A McNeish
Journal:  J Pathol       Date:  2018-02-10       Impact factor: 7.996

7.  The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.

Authors:  Dalibor Blazek; Jiri Kohoutek; Koen Bartholomeeusen; Eric Johansen; Petra Hulinkova; Zeping Luo; Peter Cimermancic; Jernej Ule; B Matija Peterlin
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

8.  QUMA: quantification tool for methylation analysis.

Authors:  Yuichi Kumaki; Masaaki Oda; Masaki Okano
Journal:  Nucleic Acids Res       Date:  2008-05-16       Impact factor: 16.971

9.  The human cap-binding complex is functionally connected to the nuclear RNA exosome.

Authors:  Peter Refsing Andersen; Michal Domanski; Maiken S Kristiansen; Helena Storvall; Evgenia Ntini; Celine Verheggen; Aleks Schein; Jakob Bunkenborg; Ina Poser; Marie Hallais; Rickard Sandberg; Anthony Hyman; John LaCava; Michael P Rout; Jens S Andersen; Edouard Bertrand; Torben Heick Jensen
Journal:  Nat Struct Mol Biol       Date:  2013-11-24       Impact factor: 15.369

10.  Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer.

Authors:  Katharina Prieske; Stefan Prieske; Simon A Joosse; Fabian Trillsch; Donata Grimm; Eike Burandt; Sven Mahner; Barbara Schmalfeldt; Karin Milde-Langosch; Leticia Oliveira-Ferrer; Linn Woelber
Journal:  Oncotarget       Date:  2017-09-15
View more
  3 in total

1.  Silencing of lncRNA MIR497HG via CRISPR/Cas13d Induces Bladder Cancer Progression Through Promoting the Crosstalk Between Hippo/Yap and TGF-β/Smad Signaling.

Authors:  Changshui Zhuang; Ying Liu; Shengqiang Fu; Chaobo Yuan; Jingwen Luo; Xueting Huang; Weifeng Yang; Wuwei Xie; Chengle Zhuang
Journal:  Front Mol Biosci       Date:  2020-12-09

2.  Exome analysis for Cronkhite-Canada syndrome: A case report.

Authors:  Zhao-Dong Li; Li Rong; Yuan-Jing He; Yu-Zhu Ji; Xiang Li; Fang-Zhou Song; Xiao-An Li
Journal:  World J Clin Cases       Date:  2022-08-26       Impact factor: 1.534

3.  Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.

Authors:  Rachel M Hurley; Cordelia D McGehee; Ksenija Nesic; Cristina Correia; Taylor M Weiskittel; Rebecca L Kelly; Annapoorna Venkatachalam; Xiaonan Hou; Nicholas M Pathoulas; X Wei Meng; Olga Kondrashova; Marc R Radke; Paula A Schneider; Karen S Flatten; Kevin L Peterson; Marc A Becker; Ee Ming Wong; Melissa S Southey; Alexander Dobrovic; Kevin K Lin; Thomas C Harding; Iain McNeish; Christian A Ross; Jill M Wagner; Matthew J Wakefield; Clare L Scott; Paul Haluska; Andrea E Wahner Hendrickson; Larry M Karnitz; Elizabeth M Swisher; Hu Li; S John Weroha; Scott H Kaufmann
Journal:  NAR Cancer       Date:  2021-07-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.